0001424884-11-000078.txt : 20110516 0001424884-11-000078.hdr.sgml : 20110516 20110516160349 ACCESSION NUMBER: 0001424884-11-000078 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110331 FILED AS OF DATE: 20110516 DATE AS OF CHANGE: 20110516 EFFECTIVENESS DATE: 20110516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAPIMMUNE INC CENTRAL INDEX KEY: 0001094038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880277072 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27239 FILM NUMBER: 11846750 BUSINESS ADDRESS: STREET 1: UNIT 2 - 3590 WEST 41ST AVENUE CITY: VANCOUVER STATE: A1 ZIP: V6N 3E6 BUSINESS PHONE: 604-264-8274 MAIL ADDRESS: STREET 1: UNIT 2 - 3590 WEST 41ST AVENUE CITY: VANCOUVER STATE: A1 ZIP: V6N 3E6 FORMER COMPANY: FORMER CONFORMED NAME: GENEMAX CORP DATE OF NAME CHANGE: 20020718 FORMER COMPANY: FORMER CONFORMED NAME: EDUVERSE COM DATE OF NAME CHANGE: 19990827 NT 10-Q 1 tpivnt10q.htm tpivnt10q.htm
 
 
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12B-25
NOTIFICATION OF LATE FILING

SEC File Number 000-27239

¨ Form 10-K  ¨Form 20-F ¨Form 11-K þForm 10-Q ¨Form 10-D ¨Form N-SAR ¨Form N-CSR

For Period Ending: March 31, 2011
 
PART I: REGISTRANT INFORMATION
 
 
Full Name of Registrant: TapImmune Inc.
  
Address of Principal Executive Office:
 
2815 Eastlake Avenue East, Suite 300
Seattle, WA 98102
(206) 336-5600
 
 PART II: RULES 12B-25(B) AND (C)
 
 
It is anticipated that the subject Quarterly Report on Form 10-Q will be filed within the next several days.
 
 
 PART III: NARRATIVE
 
 
The Registrant has not completed its Quarterly Report on Form 10-Q for the period ended March 31, 2011 due to administrative delays.
 
 
PART IV: OTHER INFORMATION
 
 
(1) Name and telephone number of person(s) to contact in regard to this notification
 
Denis Corin: 206-336-5600
 
(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
 
[X] YES [ ] NO
 

 
 
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
[ ] YES [X] NO
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
TapImmune Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
  

 
TapImmune Inc.
  
       
Dated: May 16, 2011
By:
/s/ Denis Corin
  
   
Denis Corin
  
   
President